Previous 10 | Next 10 |
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Evaxion Biotech Reaches Milestone in EVX-01 Development” Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-st...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today’s price action (prior to the Federal Reserve’s rate hike decision at least) has been broadly positive. But for investors in Evaxion Biotech (NASDAQ: EVAX ), it’s been a heck of a day. Pre...
Evaxion Biotech ( EVAX ) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck ( NY...
COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing...
COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the ...
Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference...
Evaxion Biotech ADS press release ( EVAX ): Q2 GAAP EPS of -$0.20 beats by $0.10 . As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing fac...
Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized cancer immunotherapies for melanoma Announced gonorrhea as second bacterial product target Ended second quarter with cash and cash equivalents of $25.3 ...
Evaxion Biotech ( EVAX ) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in...
COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced the following executive ma...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...